期刊文献+

多靶点酪氨酸激酶抑制剂的研究进展 被引量:2

原文传递
导出
摘要 目的:为多靶点酪氨酸激酶抑制剂在临床治疗肿瘤方面提供参考。方法:查阅国内外相关文献、网站,对已经上市的和正在进行Ⅲ期临床研究、具有良好前景的酪氨酸激酶抑制剂进行总结、分析。结果与结论:多靶点抑制剂在治疗方面优于单靶点抑制剂,多靶点联合阻断信号传导是肿瘤治疗和药物开发的新发展方向。多靶点酪氨酸激酶抑制剂作为新的靶向抗肿瘤药物,为临床治疗肿瘤提供了更多选择,特别是正在进行Ⅲ期临床试验的药物,其前景较好,值得关注。
出处 《中国药房》 CAS CSCD 2013年第13期1233-1235,共3页 China Pharmacy
  • 相关文献

参考文献12

  • 1罗富荣,陈惠孙,柏干荣.受体酪氨酸激酶信号转导途径抑制剂在肿瘤治疗中的应用[J].中国药房,2001,12(9):559-561. 被引量:5
  • 2贡联兵.酪氨酸激酶抑制剂的进展与评价[J].中国医院用药评价与分析,2006,6(6):329-332. 被引量:9
  • 3Harrisonl C, Verstovsek S, Mcmullin MF, et al. Janus ki- nase inhibition and its effect upon the therapeutic land- scape for myelofibrosis: from palliation to cure[J]. Br J Haematol, 2012,157(4) : 426.
  • 4Reixac B.Ruxolitinib. Tyrosine-protein kinase JAK1/2 in- hibitor, treatment of myelofibrosis, treatment of myelo- proliferative neoplasms, treatment of psoriasis[J]. Drugs ofthe Future,2010,35(6) :457.
  • 5Thepharmaletter. Pfizer's tasocitinib reduced signs and symptoms of rheumatoid arthritis in Ph IU study; New da- ta on Roche' s Actemra in RA[EB/OL].[2012-06-02]. http://www.thepharmaletter.com/file/99691/pfizers-tasoci- tinib-reduced-signs-and-symptoms-of-rheumatoid-arthri- tis-in-ph-iii-study-new-data-on-roches-actemra-in-ra.html.
  • 6Tedesco-Silva H, Grinyo JM, Brennan D, et al. Safety pro- file of tasocitinib (CP-690550)-based cni-free regimens in de novo kidney transplant patients in a dose/expo- sure-finding phase 2B study: results of a 6-month interim analysis: 820[J]. Transplantation, 2010,90 ( 25 ) : 201.
  • 7Minkovsky N, Berezov A. BIBW-2992, a dual receptor ty- rosine kinase inhibitor for the treatment of solid tumors [J]. Curr Opin Investig Drugs, 2008,9(12) : 1 336.
  • 8Mitry E, Hammel P, Deplanque G, et al. Safety and acti- vity of masitinib in combination with gemcitabine in pa- tients with advanced pancreatic cancer[J]. Cancer Che- mother Pharmacol, 2010,66 (2) : 395.
  • 9Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968 D1 ) reverses multidrug resistance by inhibiting the efflux func- tion of multiple ATP-binding cassette transporters[J]. Can- cerRes,2010,70(20) :7 981.
  • 10安鸿志,林晓贞,房佰俊.酪氨酸激酶抑制剂初始治疗慢性粒细胞白血病的研究进展[J].中国药房,2011,22(33):3148-3151. 被引量:9

二级参考文献33

  • 1Pawson T. Protein modules and signalling networks[J].Nature, 1995, 373(6 515): 573.
  • 2Worthen GS, Avdi N, Buhl AM, et al. FMLP activates Ras and Raf in human neutrophils. Potential role in activation of MAP kinase[J].J Clin Invest, 1994,94(2):815.
  • 3Schlessinger J.How receptor tyrosine kinases activate Ras [J]. Trends Biochem Sci, 1993, 18(8): 273.
  • 4Taga T, Kishimoto T.Signaling mechanisms through cytokine receptors that share signaltransducing receptor components[J]. Curr Opin Imnunol, 1995, 7(1): 17.
  • 5Eyers PA, Craxton M, Morrice N, et al. Conversion of SB203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution[J]. Chem Biol, 1998, 5(6) :321.
  • 6Mohammadi M, Mc Mahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors[J]. Science,1997, 276(5 314) :955.
  • 7Jonuleit T, Peschel C, Schwab R, at al. Bcr Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors[J] .Br J Haematol,1998, 100(2): 295.
  • 8Carroll M, Ohno Jones S, Tamura S, et al. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR ABL, TEL-ABL and TEL-PDGR fusion proteins[J]. Blood, 1997, 90(12): 4 947.
  • 9Le Coutre P. Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukaemia cells with an ABL kinase inhibitor[J].J Natl Cancer Inst,1999, 91(2): 163.
  • 10Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes form healthy humans[J].J Biol Chem, 1998,273(34):21 682.

共引文献20

同被引文献19

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部